Reproductive Health | |
A case–control observational study of insulin resistance and metabolic syndrome among the four phenotypes of polycystic ovary syndrome based on Rotterdam criteria | |
Talha Al-Shawaf1  Namir G Al-Tawil3  Shahla K Alalaf2  Avin S Jamil2  | |
[1] Department of Primary Care and Public Health, Imperial College, London, UK;Department of Obstetrics and Gynecology, College of Medicine, Hawler Medical University, P.O. Box 383–65, Erbil, Iraq;Department of Community Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq | |
关键词: Hyperandrogenism; Metabolic syndrome; Insulin resistance; Rotterdam phenotypes; PCOS; | |
Others : 1131903 DOI : 10.1186/1742-4755-12-7 |
|
received in 2014-10-14, accepted in 2015-01-09, 发布年份 2015 | |
【 摘 要 】
Background
Polycystic ovary syndrome (PCOS) is associated with an increased risk of insulin resistance (IR), metabolic syndrome (MetS), impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM). Metabolic aspects of the four PCOS phenotypes remain to be fully defined. The aim of this study was to compare metabolic parameters and insulin resistance among the four PCOS phenotypes defined according to the Rotterdam criteria and to determine predictors of these complications.
Methods
A total of 526 reproductive-aged women were included in this observational case–control study. Of these, 263 were diagnosed as a PCOS based on Rotterdam criteria and 263 infertile women with no evidence of PCOS were recruited as controls. Biochemical, metabolic and insulin resistance parameters were compared in the two groups and the frequency of MetS and IR were compared among the four phenotypes. Data were analyzed for statistical significance using Student’s t-test and one way analysis of variance followed by a post-hoc test (least significant difference). Chi-square tests were used to compare proportions. Univariate and multivariate logistic regression analyses were also applied.
Results
IR was identified in 112 (42.6%) of the PCOS women and 45 (17.1%) of the control (P <0.001). There were no significant differences in the frequency of IR and MetS between the four PCOS phenotypes. Homeostatic model assessment for IR (HOMA-IR) ≥3.8 was the most common IR parameter in PCOS and control groups. Women with oligo-anovulation (O) and PCO morphology (P) had a significantly lower level of 2-h postprandial insulin compared to women with O, P and hyperandrogenism (H) phenotypes.
Logistic regression analysis showed that body mass index, waist circumference, triglyceride/high-density lipoprotein ratio (cardiovascular risk), HOMA-IR and glucose abnormalities (T2DM) were associated with increased risk of having MetS (P < 0.05).
Conclusions
PCOS women with (O + P) show milder endocrine and metabolic abnormalities. Although, there were no significant differences in IR, MetS and glucose intolerance between the four PCOS phenotypes, women with PCOS are at higher risk of impaired glucose tolerance and undiagnosed diabetes.
【 授权许可】
2015 Jamil et al.; licensee BioMed Central.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
20150303114848578.pdf | 178KB | download |
【 参考文献 】
- [1]Norman RJ, Dewially D, Legro RS, Hickey TE: Polycystic ovary syndrome. Lancet 2007, 370:685-97.
- [2]Glintborg D, Henriksen JE, Andersen M, Hagen C, Hangaard J, Rasmussen PE, Schousboe K, Hermann AP: Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. Fertil Steril 2004, 82:1570-9.
- [3]Glintborg D, Andersen M: An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 2010, 26:281-96.
- [4]Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. J Clin Endocrinol Metab 1993, 329:1988-92.
- [5]Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endoc Rev 1997, 18:774-800.
- [6]Legro RS, Kunselman AR, Dodson WC, Dunaif A: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165-169.
- [7]Diamanti-Kandarakis E, Dunaif A: Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endoc Rev 2012, 33(6):981-1030.
- [8]Vigil P, Contreras P, Alvarado JL, Godoy A, Salgado AM, Cortés ME: Evidence of subpopulations with different levels of insulin resistance in women with polycystic ovary syndrome. Hum Reprod 2007, 22(11):2974-80.
- [9]Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD: Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health—National Heart, Lung, and Blood Institute sponsored women’s ischemia syndrome evaluation. J Clin Endocrinol Metab 2008, 93(4):1276-84.
- [10]Ciampelli M, Leoni F, Cucinelli F, Mancuso S, Panunzi S, De Gaetano A, Lanzone A: Assessment of insulin sensitivity from measurements in the fasting state and during an oral glucose tolerance test in polycystic ovary syndrome and menopausal patients. J Clin Endocrinol Metab 2005, 90:1398-406.
- [11]Panidis D, Tziomalos K, Misichronis G, Papadakis E, Betsas G, Katsikis I, Macut D: Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum Reprod 2011, 27(2):541-9.
- [12]Moran L, Teede H: Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009, 15:477-88.
- [13]Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF: Task force on the phenotype of the polycystic ovary syndrome of the androgen excess and PCOS Society. The androgen excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009, 91:456-88.
- [14]Gluszak O, Stopinska-Gluszak U, Glinicki P, Kapuscinska R, Snochowska H, Zgliczynski W, Debski R: Phenotype and metabolic disorders in polycystic ovary syndrome. ISRN Endocrinol 2012, 2012:569862.
- [15]Hosseinpanah F, Barzin M, Keihani S, Tehrani FR, Azizi F: Metabolic aspects of different phenotypes of polycystic ovary syndrome: Iranian PCOS Prevalence Study. Clin Endocrinol (Oxf) 2014, 81(1):93-9.
- [16]Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H: Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod 2012, 27(10):3067-73.
- [17]Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004, 81:19-25.
- [18]American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 2013, 1:S11.
- [19]Legro RS, Castracane VD, Kauffman RP: Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstetrics Gynecol Survey 2004, 59:141-54.
- [20]Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-10.
- [21]Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-9.
- [22]Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999, 22(9):1462-70.
- [23]National Institute of Health: Third report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication 2007, 1:01-3670.
- [24]Yilmaz M, Isaoglu U, Delibas IB, Kadanali S: Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res 2011, 37:1020-6.
- [25]Zhang J, Fan P, Liu H, Bai H, Wang Y, Zhang F: Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west Chinese women with PCOS. Hum Reprod 2012, 27:2484-93.
- [26]Tehrani FR, Rashidi H, Khomami MB, Tohidi M: The prevalence of metabolic disorders in various phenotypes of polycystic ovary syndrome: a community based study in southwest of Iran. Reprod Biol Endocrinol 2014, 12:89. BioMed Central Full Text
- [27]Welt CK, Gudmundsson JA, Arsson G, Adams J, Palsdottir H, Gudlaugsdottir G, et al.: Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006, 91:4842-8.
- [28]Thathapudi S, Kodati V, Erukkambattu J, Katragadda A, Addepally U, Hasan Q: Anthropometric and biochemical characteristics of polycystic ovarian syndrome in South Indian women using AES-2006 criteria. Int J Endocrinol Metab 2014, 12(1):e12470.
- [29]Amato MC, Galluzzo A, Finocchiaro S, Criscimanna A, Giordano C: The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Clin Endocrinol (Oxf) 2008, 69(1):52-60.
- [30]Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD: Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 2008, 198:670.
- [31]Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ: Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod 2009, 24:710-7.
- [32]Barber TM, Wass JA, McCarthy MI, Franks S: Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. Clin Endocrinol 2007, 66:513-7.
- [33]Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P: Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab 2006, 91:3922-7.
- [34]Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A: Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007, 88(5):1389-95.
- [35]Guastella E, Longo RA, Carmina E: Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 2010, 94:2197-201.
- [36]Chang WY, Knochenhauer ES, Bartolucci AA, Aziz R: Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups. Fertil Steril 2005, 83:1343-6.
- [37]Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY: Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 2008, 23:1924-31.
- [38]Ehrmann D, Barnes R, Rosenfield R, Cavaghan M, Imperial J: Prevalence and predictors of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22:141-6.
- [39]Kulshreshtha B, Singh S, Arora A: Family background of Diabetes Mellitus, obesity and hypertension affects the phenotype and first symptom of patients with PCOS. Gynecol Endocrinol 2013, 29:1040-4.
- [40]Skrha J, Haas T, Sindelka G, Prázný M, Widimský J, Cibula D, Svacina S: Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders. J Clin Endocrinol Metab 2004, 89:135-41.
- [41]Svendsen PF, Madsbad S, Nilas L: The insulin-resistant phenotype of polycystic ovary syndrome. Fertil Steril 2010, 94(3):1052-8.